Header Logo

Connection

BRYAN K KEE to Receptor, ErbB-2

Back to Details
This is a "connection" page, showing publications BRYAN K KEE has written about Receptor, ErbB-2.
BRYAN K KEE
Connection Strength
0.027
Receptor, ErbB-2
  1. A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation. Cancer Chemother Pharmacol. 2023 08; 92(2):107-118.
    View in: PubMed
    Score: 0.027
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.